Navigation Links
Viral Genetics' Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference
Date:9/16/2009

SAN MARINO, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Dr. M. Karen Newell, Ph.D., a lead scientist at biotechnology company Viral Genetics (Pink Sheets: VRAL), will address the 11th Annual SoCalBio Investor and Partnership Conference. Dr. Newell's presentation entitled: "The Impact of Custom Peptides on Chronic Inflammation," will take place mid-morning on Thursday, September 17, 2009. The conference is being held at The Loews Santa Monica Beach Hotel in Santa Monica, California.

Dr. Newell's presentation will include a review of Viral Genetics' previous clinical trials of its HIV/AIDS drug compound VGV-1 and other therapies, as well as the outcome of more recent studies into the mechanism of those therapies. She will cover Viral Genetics' rationale for the current product--custom targeted peptides for conditions characterized by, or requiring in the case of HIV/AIDS---chronic inflammation.

ABOUT VIRAL GENETICS:

Headquartered in San Marino, California, Viral Genetics discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company has an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the company) to license technology developed by M. Karen Newell, Ph.D., that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics has formed a wholly owned subsidiary, MetaCytoLytics, Inc, to advance a technology developed by University of Colorado Professor M. Karen Newell called "metabolic disruption technology" (MDT), which focuses on blocking a tumor cell's ability to generate energy from glucose or from fatty acids. Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado.
'/>"/>

SOURCE Viral Genetics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
2. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
3. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
4. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
5. Viral Genetics Creates Subsidiary to Develop Cancer Therapy
6. Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
7. Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
8. New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
9. BIO Visitors Bring Viral Preparedness to Atlanta
10. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
11. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...recently announced that Dr. Dominique Hebrault wil...ss Analytical Technology (PAT) in Green Chemistry ... , (PRWEB) November 20, 20...echnology (PAT) in Green Chemistry and Green Engin...Technology (PAT) case studies will be presented on...
(Date:11/19/2009)...swire/ -- Dr. Mate Hidvegi, inventor of Avemar fer...ease issued on November 17 by Biropharma Kft, disc...d self-serving statements about its U.S. competito...from his office in Budapest, Hungary: ,, "The ...apply to AveULTRA, www.aveultra.com , is mislea...
(Date:11/19/2009)...Mass., Nov. 19 Arlington Medical R...e leading driver of antibiotic selection in nosoco...y against gram-positive and gram-negative pathogen...nosocomial pneumonia, surveyed European physicians...rovide appropriate coverage against common pathoge...
(Date:11/19/2009)...e Synthesis Companies Form International Gene Synt...es in Risk Reduction ,Five Member Companies Repr...ity , (PRWEB) November 19...ynthesis companies today announced agreement that ...mote biosecurity in the gene synthesis industry. ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
..., December 11 , - New ,Trophon EPR, Device ...ultrasound transducer disinfection are in many cas...he latest alarming result,issued by the Center for... US,public health agency, in its recently publishe...Healthcare Facilities (1). The guideline is the CD...
...1 Delcath Systems, Inc. (Nasdaq: DCTH ), a me...ercutaneous Hepatic Perfusion ("PHP") System for t...day that the first fifty percent (46 of 92) of pat... trial treating metastatic cutaneous and ocular me...cer centers in this trial continue to evaluate and...
... Alimera Sciences Inc., a privately held,biopharm..., development and,commercialization of prescriptio...enrollment has begun for a pilot study to assess t...with bilateral geographic atrophy (GA) secondary t...The pilot study will compare two doses of Iluvien ...
Other Biology Technology:Ultrasound Transducer Disinfection in Many Cases Insufficient 2Ultrasound Transducer Disinfection in Many Cases Insufficient 3Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...2: The offspring of two inbred strains tend to be ...the gene-level variability that leads to this phen...boost our ability to custom-tailor crops for speci... consumption or high glucose content for biomass f...quence of the common corn strain B73, University o...
(Date:11/19/2009)...nable farming, initially adopted to preserve soil ...le in maintaining a healthy climate, according to ...e and Los Alamos national laboratories. , ORNL a...al of the earth,s soils to sequester carbon, with ...ld greatly reduce U.S. carbon emissions by as much...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 2ORNL, Los Alamos pioneer new approach to assist scientists, farmers 3Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 1Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 2Seattle Childrens Hospital Deploys CAs Integrated Infrastructure and Performance Management Solution 52930 3Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 1Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 2Abbott to Acquire Nutrition Businesses Expanding Presence in India 52926 3Must Haves for Your Summer Vacation Bag 52922 1Must Haves for Your Summer Vacation Bag 52922 2Must Haves for Your Summer Vacation Bag 52922 3
...ma Barkai will receive the Helen and Martin Kimmel.... 5 at the Weizmann Institute. The award is accomp...r five years. , Taking a chance on an experiment ... Living cells are, from this angle, great subjects...have all sorts of interesting consequences for man...
...e in the November 2007 issue of BioScience describ...llenges of green roofsroofs with a vegetated surfa...struct than a typical roof, a green roof can reduc...trol storm-water runoff. Green roofs also provide ... less common in the United States than in Japan an...
... Far removed from streams of gas-thirsty cars and ...er in global climate change. Circling the norther... - one of the largest ecosystems on earth - act as...vels. , Forest ecologists at the University of Wi...tors such as forest fires and climate influence ca...
Other Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Wildfire drives carbon levels in northern forests 2
Rabbit Anti-JNK3 / SAPK1b Monoclonal Antibody, Unconjugated, Clone C05T from Upstate
...ays research and biologic production demands on ce...irming viable cell populations. Therefore, both ce...st be determined accurately and precisely. The new...omatic and cost effective means to perform the try...
...cosylation is a post-translational modification th..., including immune regulation, inflammation, cell-...chnology has developed two lectin based Glycoprote... Germ Agglutinin (WGA), that allow isolation of gl...
...eLINK Bioconjugation Kit provides a powerful yet s...carbohydrates and nuceleic acids. The kit provides... with reagents for quantifying conjugation efficie...uding enzymes, fluorophores, biotin and other tags...
Biology Products: